Intracellular Pathogen Persistence Module

Module intracellular_pathogen_persistence 6 disorders Pathograph 2

A conserved antibacterial lifestyle-gating module representing the intracellular niche occupied by obligate and facultative intracellular bacteria (e.g. Rickettsia, Bartonella, Brucella, Coxiella, Legionella, Chlamydia, Mycobacterium, intracellular phases of others). Unlike the cell-wall and protein-synthesis modules, the nodes here are not a single drug target but a pharmacokinetic gating principle: the pathogen resides inside host cells where hydrophilic, poorly cell-penetrant antibiotics — chiefly the beta-lactams — cannot accumulate, so they fail regardless of intrinsic susceptibility. Effective therapy requires agents that concentrate intracellularly: tetracyclines (doxycycline), macrolides, fluoroquinolones, and rifamycins. This module encodes WHY drug choice for intracellular infections departs from "any bactericidal antibiotic" and complements the target-based modules: a conforming disease may inhibit a ribosomal or cell-wall target, but only with a drug that first reaches the intracellular compartment.

⚙

Pathophysiology Nodes

2 shared nodes are defined in this module.

◉

Cell Types

No cell types are annotated for this module.

⇄

Biological Processes

Notes

This is an antibacterial drug-mechanism (lifestyle-gating) module, not a specific disease. Disorder entries for intracellular bacterial infections reference nodes via conforms_to (e.g., "intracellular_pathogen_persistence#Intracellular Niche and Beta-Lactam Exclusion"), and their treatments point at the cell-penetrant requirement node via target_mechanisms. Key conformance / treatment target: "Requirement for Cell-Penetrant Antimicrobials" (the doxycycline/macrolide/fluoroquinolone/ rifamycin rationale). The nodes are gating principles, not enzyme targets; a conforming disease typically ALSO conforms to a target-based module (ribosome/cell wall) for the drug's molecular mechanism, with this module explaining the penetration constraint on which agents qualify.

↗

Used By Disorder Entries

Legionnaires Disease via Inhalation and Intracellular Replication in Alveolar Macrophages → Intracellular Niche and Beta-Lactam Exclusion , Requirement for Cell-Penetrant Antimicrobials

Leprosy via Intracellular Residence in Macrophages and Schwann Cells (Cell-Penetrant Drug Requirement) → Intracellular Niche and Beta-Lactam Exclusion

Murine typhus via Obligate Intracellular Niche (Cell-Penetrant Drug Requirement) → Intracellular Niche and Beta-Lactam Exclusion

Oroya fever via Intracellular Niche in Erythrocytes and Endothelium (Cell-Penetrant Drug Requirement) → Intracellular Niche and Beta-Lactam Exclusion

Psittacosis via Inhalation and Obligate Intracellular Chlamydial Infection → Intracellular Niche and Beta-Lactam Exclusion

Q Fever via Inhalation and Intracellular Replication in Alveolar Macrophages → Intracellular Niche and Beta-Lactam Exclusion , Coxiella-Containing Vacuole Biogenesis and Dot/Icm Effector Secretion → Intracellular Niche and Beta-Lactam Exclusion

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence-backed metadata.

⚙

Pathophysiology

Intracellular Niche and Beta-Lactam Exclusion

intrinsic resistance

Obligate and facultative intracellular bacteria invade and persist within host cells (phagocytes, endothelium, epithelium), where they are shielded from antibodies, complement, and — critically for therapy — from antibiotics that cannot cross or accumulate within the eukaryotic cell membrane. The beta-lactams are the paradigm case: they diffuse poorly into and do not concentrate within host cells, so they are ineffective against intracellular pathogens even when the organism is susceptible in vitro. This is the gating principle that excludes cell-wall-active therapy for this class of infection.

Biological Process Involved in Interaction with Host GO:0051701

Used by disorders

Legionnaires Disease as Inhalation and Intracellular Replication in Alveolar Macrophages

Leprosy as Intracellular Residence in Macrophages and Schwann Cells (Cell-Penetrant Drug Requirement)

Murine typhus as Obligate Intracellular Niche (Cell-Penetrant Drug Requirement)

Oroya fever as Intracellular Niche in Erythrocytes and Endothelium (Cell-Penetrant Drug Requirement)

Psittacosis as Inhalation and Obligate Intracellular Chlamydial Infection

Q Fever as Coxiella-Containing Vacuole Biogenesis and Dot/Icm Effector Secretion

Q Fever as Inhalation and Intracellular Replication in Alveolar Macrophages

Downstream

Requirement for Cell-Penetrant Antimicrobials Because the niche excludes poorly penetrant drugs, effective therapy is restricted to agents that accumulate intracellularly.

Requirement for Cell-Penetrant Antimicrobials

therapeutic vulnerability

Therapeutic efficacy against intracellular bacteria tracks the intracellular concentration the drug achieves, not just its in vitro MIC. Tetracyclines (doxycycline), macrolides, fluoroquinolones, and rifamycins accumulate within host cells and are therefore the mainstays for rickettsioses, bartonelloses, brucellosis, Q fever, Legionella and Mycoplasma pneumonia, and chlamydial infection. This node is the cell-penetrant-drug requirement that conforming intracellular-infection treatments target; the drug's molecular target (usually the ribosome) is captured by the relevant target-based module.

Response to Antibiotic GO:0046677

Used by disorders

Legionnaires Disease